Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26099797 | 0.81 | MEN1 (0.35) | MEN1KMT2AALDH1A1TSHRCTSL | |
| SCHEMBL26097837 | 0.81 | MEN1 (0.35) | MEN1KMT2AALDH1A1TSHRCTSL | |
| SCHEMBL26099671 | 0.81 | MEN1 (0.34) | MEN1KMT2AALDH1A1TSHRCTSL | |
| SCHEMBL26097516 | 0.80 | ALDH1A1 (0.34) | MEN1KMT2AALDH1A1TSHRCTSL | |
| SCHEMBL5806647 | 0.78 | MEN1 (0.39) | MEN1KMT2AALDH1A1TSHRCTSL | |
| SCHEMBL30181505 | 0.78 | MEN1 (0.39) | MEN1KMT2AALDH1A1TSHRCTSL | |
| SCHEMBL17034797 | 0.78 | MEN1 (0.39) | MEN1KMT2AALDH1A1TSHRCTSL | |
| SCHEMBL17495321 | 0.77 | MEN1 (0.38) | MEN1KMT2AALDH1A1TSHRCTSL | |
| SCHEMBL26471708 | 0.74 | MEN1 (0.39) | MEN1KMT2AALDH1A1TSHRCTSL | |
| SCHEMBL26098930 | 0.73 | MEN1 (0.30) | MEN1KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | MEN1 2856/4885KMT2A 2770/4885ALDH1A1 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.